{
    "nct_id": "NCT06459180",
    "official_title": "A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)",
    "inclusion_criteria": "* Has histologically-confirmed diagnosis of squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix\n* Must have recurrent or metastatic cervical cancer that has progressed on or after treatment with 1 prior line of systemic platinum doublet chemotherapy (with or without bevacizumab) AND must have received anti-PD-1/anti-PD-L1 therapy as part of prior cervical cancer regimens\n* Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, as assessed by the investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions\n* Is assigned female sex at birth, at least 18 years of age at the time of providing the informed consent\n* Has ECOG performance status of 0 or 1 within 7 days before allocation for the Sacituzumab Tirumotecan Run-in or within 7 days before randomization for the Phase 3 portion\n* Has provided tumor tissue (most recent sample is preferred) from a core or excisional biopsy of a tumor lesion not previously irradiated\n* HIV-infected participants must have well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART)\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation (Sacituzumab Tirumotecan Run-in) or randomization (Phase 3 portion)\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Has adequate organ function\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has Grade ≥2 peripheral neuropathy\n* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.\n* Received prior systemic anticancer therapy\n* Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed\n* Has histological subtypes of cervical cancer other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (eg, carcinosarcoma) or nonepithelial cancer (eg, sarcoma, neuroendocrine tumors)\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Active infection requiring systemic therapy\n* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease\n* Concurrent active Hepatitis B and active Hepatitis C virus infection\n* Severe hypersensitivity (≥Grade 3) to sacituzumab tirumotecan or treatment of physician's choice (TPC) and/or any of their excipients, or other biologic therapy\n* Participants who have not adequately recovered from major surgery or have ongoing surgical complications\n* Has a history of (noninfectious) pneumonitis/ILD that required steroids or has current pneumonitis/ILD",
    "miscellaneous_criteria": ""
}